Details of the Drug
General Information of Drug (ID: DM0A3DB)
| Drug Name |
6-bromo-N-(3-chlorophenyl)quinazolin-4-amine
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
6-bromo-N-(3-chlorophenyl)quinazolin-4-amine; CHEMBL1079374; AC1LEZQW; C14H9BrClN3; ChemDiv1_028574; Oprea1_590274; Neuro1_000364; MLS000572427; cid_720635; SCHEMBL4783154; HMS668C18; MolPort-000-660-268; ZINC122236; HMS2493B23; BDBM50311887; STK965864; AKOS002348868; MCULE-5418328745; SMR000194385; EU-0077259; ST50477345; 6-bromo-N-(3-chlorophenyl)-4-quinazolinamine; (6-bromoquinazolin-4-yl)(3-chlorophenyl)amine; SR-01000485096; SR-01000485096-1
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 334.6 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 4.7 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


